NEW YORK (GenomeWeb News) – Caprion Proteomics said today that it has acquired the biomarker services division of PPD, a contract research firm focused on pharmaceutical services based in Wilmington, NC, for an undisclosed sum.
Montreal-based Caprion said that it closed the acquisition of PPD Biomarker Discovery Services on December 31, 2009.
Caprion said that it will fulfill PPD’s existing contractual biomarker obligations from its Montreal facilities and from a new US facility to be called Caprion Proteomics, US.
The acquisition will firm up Caprion’s position in the proteomics and biomarker services and will broaden its client portfolio and revenue base, the company said.
“By acquiring this business, we will expand our capacity and be able to better meet the growing biomarker needs of our current and future clients,” Caprion President and CEO Martin LeBlanc said in a statement.